Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
Pharma News
Global branded generics market expected to double by 2026
VALLEY COTTAGE, N.
Adapt Pharma gets FDA approval for 2-mg Narcan Nasal Spray
SILVER SPRING, Md.
FDA approves 72 mcg dose of Linzess for chronic idiopathic constipation
CAMBRIDGE, Mass.
Low levels of glucose in the brain may trigger Alzheimer's
Our brain runs on sugar, and new research links the lack of glucose with cognitive impairment typical of Alzheimer's disease and dementia.
Antibiotics can boost bacterial growth
London.
Malaria drugs fail for first time on patients in UK
A key malaria treatment has failed for the first time in patients being treated in the UK, doctors say.
Novel drug delivery platform brings good news in Phase III trial
Privately-owned Foresee Pharmaceuticals has announced top-line results from a Phase III study of its investigational prostate cancer drug FP-001 LMIS (leuprolide mesylate injectable suspension)...
First-in-class anemia drug passes pivotal clinical test
San Francisco, USA-headquartered FibroGen (Nasdaq.
Shark-inspired drug may help treat fibrosis, researchers say
Australian scientists hope a drug that mimics part of a shark's immune system may help treat an incurable lung disease.
Novo Nordisk enters collaboration with University of Oxford on type 2 diabetes and invests GBP 115m in new research centre
University of Oxford and Novo Nordisk today announced a landmark research collaboration focused on type 2 diabetes.
WHO seeks new leader to rebuild damaged reputation
The list of candidates to lead the World Health Organization (WHO) and rebuild its battered reputation after its slow response to West Africa's deadly Ebola outbreak was whittled down to t...
Johnson & Johnson’s $30 Billion Cash Deal Is Finally Happening
Swiss biotech company Actelion said on Thursday it had agreed to be purchased by Johnson & Johnson in a $30 billion all-cash deal, following weeks of speculation a deal was imminent.
533
534
535
536
537
538
539
540
541
